BLCO (Bausch & Lomb) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


BLCO Bausch & Lomb Corp BLCO
77 GF Score
Price $15.91
GF Value $18.60
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Bausch & Lomb Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Bausch & Lomb's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BLCO vs ISRG, BDX, MDLN: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch & Lomb Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Margin of Safety % (DCF Earnings Based) falls into.


BLCO
77GF Score
Bausch & Lomb Corp BLCO
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $15.91 is trading 14.5% below its estimated GF Value™ of $18.60. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for BLCO:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $18.60 vs. price of $15.91 (14.5% below fair value)
  • GF Score™: 77/100 with 8 warning signs

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch & Lomb Business Description

Other Exchanges S2L:GermanyBLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for BLCO

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.91
Price
$18.60
GF Value